High blood levels of FCRL5 — a protein mainly found in certain B-cells, a type of immune cell — are linked with a greater likelihood of achieving and maintaining a complete response to rituximab in people with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA),…

People with ANCA-associated vasculitis (AAV) are at a greater risk of venous thromboembolism — blood clots in veins — if they have evidence of bleeding into the lungs, heart involvement, red blood cells in their urine, or anti-PR3-ANCA autoantibodies, according to a study in patients of a Phase…

Although serum levels of the pro-inflammatory molecule interleukin (IL)-6 do not predict who will achieve complete remission, increases during periods of no disease activity are associated with subsequent severe relapses in patients with ANCA-associated vasculitis (AAV) on rituximab, according to an exploratory study. The research, “The…

Patients with ANCA-associated vasculitis (AAV) experience significant increases in serum lipid levels during remission induction, particularly those who are newly diagnosed or have anti-PR3 antibodies, according to new research. The findings also indicated that disease phase and antibody type are associated with differential levels of inflammation and could…

Real-world use of MabThera (rituximab) as an induction treatment for patients with ANCA-associated vasculitis (AAV) on low-dose prednisone led to successful complete remission rates that matched those seen in a key clinical trial, according to a study. However, the investigators believe that the increasing number of relapses after treatment…